Literature DB >> 16127459

Alzheimer disease beta-amyloid activity mimics cholesterol oxidase.

Luigi Puglielli1, Avi L Friedlich, Kenneth D R Setchell, Seiichi Nagano, Carlos Opazo, Robert A Cherny, Kevin J Barnham, John D Wade, Simon Melov, Dora M Kovacs, Ashley I Bush.   

Abstract

The abnormal accumulation of amyloid beta-peptide (Abeta) in the form of senile (or amyloid) plaques is one of the main characteristics of Alzheimer disease (AD). Both cholesterol and Cu2+ have been implicated in AD pathogenesis and plaque formation. Abeta binds Cu2+ with very high affinity, forming a redox-active complex that catalyzes H2O2 production from O2 and cholesterol. Here we show that Abeta:Cu2+ complexes oxidize cholesterol selectively at the C-3 hydroxyl group, catalytically producing 4-cholesten-3-one and therefore mimicking the activity of cholesterol oxidase, which is implicated in cardiovascular disease. Abeta toxicity in neuronal cultures correlated with this activity, which was inhibited by Cu2+ chelators including clioquinol. Cell death induced by staurosporine or H2O2 did not elevate 4-cholesten-3-one levels. Brain tissue from AD subjects had 98% more 4-cholesten-3-one than tissue from age-matched control subjects. We observed a similar increase in the brains of Tg2576 transgenic mice compared with nontransgenic littermates; the increase was inhibited by in vivo treatment with clioquinol, which suggests that brain Abeta accumulation elevates 4-cholesten-3-one levels in AD. Cu2+-mediated oxidation of cholesterol may be a pathogenic mechanism common to atherosclerosis and AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16127459      PMCID: PMC1190368          DOI: 10.1172/JCI23610

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid.

Authors:  Kevin J Barnham; Fredrik Haeffner; Giuseppe D Ciccotosto; Cyril C Curtain; Deborah Tew; Christine Mavros; Konrad Beyreuther; Darryl Carrington; Colin L Masters; Robert A Cherny; Roberto Cappai; Ashley I Bush
Journal:  FASEB J       Date:  2004-07-01       Impact factor: 5.191

2.  The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice.

Authors:  Joo-Yong Lee; Jonathan E Friedman; Itzchak Angel; Alex Kozak; Jae-Young Koh
Journal:  Neurobiol Aging       Date:  2004 Nov-Dec       Impact factor: 4.673

3.  In vivo reduction of amyloid-beta by a mutant copper transporter.

Authors:  Amie L Phinney; Bettina Drisaldi; Stephen D Schmidt; Stan Lugowski; Veronica Coronado; Yan Liang; Patrick Horne; Jing Yang; Joannis Sekoulidis; Janaky Coomaraswamy; M Azhar Chishti; Diane W Cox; Paul M Mathews; Ralph A Nixon; George A Carlson; Peter St George-Hyslop; David Westaway
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

4.  Mass spectrometry in structural and stereochemical problems. 78. Steroidal delta-4-3,6-diketones.

Authors:  C Djerassi; J Karliner; R T Aplin
Journal:  Steroids       Date:  1965-07       Impact factor: 2.668

5.  Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts.

Authors:  Shayne A Bellingham; Giuseppe D Ciccotosto; B Elise Needham; Lisa R Fodero; Anthony R White; Colin L Masters; Roberto Cappai; James Camakaris
Journal:  J Neurochem       Date:  2004-10       Impact factor: 5.372

6.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial.

Authors:  Craig W Ritchie; Ashley I Bush; Andrew Mackinnon; Steve Macfarlane; Maree Mastwyk; Lachlan MacGregor; Lyn Kiers; Robert Cherny; Qiao-Xin Li; Amanda Tammer; Darryl Carrington; Christine Mavros; Irene Volitakis; Michel Xilinas; David Ames; Stephen Davis; Konrad Beyreuther; Rudolph E Tanzi; Colin L Masters
Journal:  Arch Neurol       Date:  2003-12

7.  The ACAT inhibitor CP-113,818 markedly reduces amyloid pathology in a mouse model of Alzheimer's disease.

Authors:  Birgit Hutter-Paier; Henri J Huttunen; Luigi Puglielli; Christopher B Eckman; Doo Yeon Kim; Alexander Hofmeister; Robert D Moir; Sarah B Domnitz; Matthew P Frosch; Manfred Windisch; Dora M Kovacs
Journal:  Neuron       Date:  2004-10-14       Impact factor: 17.173

8.  Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice.

Authors:  Thomas A Bayer; Stephanie Schäfer; Andreas Simons; André Kemmling; Thomas Kamer; Ralf Tepest; Anne Eckert; Katrin Schüssel; Oliver Eikenberg; Christine Sturchler-Pierrat; Dorothee Abramowski; Matthias Staufenbiel; Gerd Multhaup
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-14       Impact factor: 11.205

9.  Metabolite-initiated protein misfolding may trigger Alzheimer's disease.

Authors:  Qinghai Zhang; Evan T Powers; Jorge Nieva; Mary E Huff; Maria A Dendle; Jan Bieschke; Charles G Glabe; Albert Eschenmoser; Paul Wentworth; Richard A Lerner; Jeffery W Kelly
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-19       Impact factor: 11.205

10.  Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution.

Authors:  Giuseppe D Ciccotosto; Deborah Tew; Cyril C Curtain; Danielle Smith; Darryl Carrington; Colin L Masters; Ashley I Bush; Robert A Cherny; Roberto Cappai; Kevin J Barnham
Journal:  J Biol Chem       Date:  2004-07-28       Impact factor: 5.157

View more
  38 in total

1.  Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.

Authors:  Hailin Zheng; Moussa B H Youdim; Mati Fridkin
Journal:  ACS Chem Neurosci       Date:  2010-10-04       Impact factor: 4.418

2.  A new approach to the molecular analysis of docking, priming, and regulated membrane fusion.

Authors:  Tatiana P Rogasevskaia; Jens R Coorssen
Journal:  J Chem Biol       Date:  2011-02-08

3.  Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins.

Authors:  Ian V J Murray; Liu Liu; Hiroaki Komatsu; Kunihiro Uryu; Gang Xiao; John A Lawson; Paul H Axelsen
Journal:  J Biol Chem       Date:  2007-01-24       Impact factor: 5.157

4.  Hydrogen peroxide triggered prochelator activation, subsequent metal chelation, and attenuation of the fenton reaction.

Authors:  Yibin Wei; Maolin Guo
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

5.  Cytochrome P450 27A1 Deficiency and Regional Differences in Brain Sterol Metabolism Cause Preferential Cholestanol Accumulation in the Cerebellum.

Authors:  Natalia Mast; Kyle W Anderson; Joseph B Lin; Yong Li; Illarion V Turko; Curtis Tatsuoka; Ingemar Bjorkhem; Irina A Pikuleva
Journal:  J Biol Chem       Date:  2017-02-11       Impact factor: 5.157

6.  Regulation of presynaptic strength by controlling Ca2+ channel mobility: effects of cholesterol depletion on release at the cone ribbon synapse.

Authors:  Aaron J Mercer; Robert J Szalewski; Skyler L Jackman; Matthew J Van Hook; Wallace B Thoreson
Journal:  J Neurophysiol       Date:  2012-03-21       Impact factor: 2.714

7.  Elevated copper in the amyloid plaques and iron in the cortex are observed in mouse models of Alzheimer's disease that exhibit neurodegeneration.

Authors:  Megan W Bourassa; Andreana C Leskovjan; Ryan V Tappero; Erik R Farquhar; Carol A Colton; William E Van Nostrand; Lisa M Miller
Journal:  Biomed Spectrosc Imaging       Date:  2013-04-01

8.  Cholesterol potentiates beta-amyloid-induced toxicity in human neuroblastoma cells: involvement of oxidative stress.

Authors:  Patricia Ferrera; Octavio Mercado-Gómez; Martín Silva-Aguilar; Mahara Valverde; Clorinda Arias
Journal:  Neurochem Res       Date:  2008-02-21       Impact factor: 3.996

Review 9.  Therapeutics for Alzheimer's disease based on the metal hypothesis.

Authors:  Ashley I Bush; Rudolph E Tanzi
Journal:  Neurotherapeutics       Date:  2008-07       Impact factor: 7.620

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.